Exagen Inc. (XGN)

1,5700 +0,1700 (+12,14%) Alla chiusura: 04:00PM EDT

Exagen Inc.

1261 Liberty Way
Suite C
Vista, CA 92081
United States
760 560 1501
https://www.exagen.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 174

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Tina S. Nova Ph.D.	Executive Chairman of the Board of Directors	100,88k	N/D	1954
Mr. John Aballi	CEO, President & Director	931,95k	N/D	1985
Mr. Kamal Adawi M.S., MBA	CFO & Corporate Secretary	676,09k	N/D	1979
Ryan Douglas	Investors Relations Officer	N/D	N/D	N/D
Mr. John Wegener	Senior Vice President of Sales and Marketing	N/D	N/D	1969
Dr. Andrew L. Concoff FACR, M.D.	Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board	N/D	N/D	N/D
Dr. Michael I. Nerenberg M.D.	Chief Medical Officer	N/D	N/D	1955

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Governance aziendale

L'ISS Governance QualityScore di Exagen Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.